The potential role of antisense oligodeoxynucleotide therapy for cardiovascular disease

Drugs

Volumn 60, Issue 2, 2000, Pages 239-248

  Phillips, M I ^a   Galli, S M ^a   Mehta, J L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; VIRUS VECTOR;

CARDIOVASCULAR DISEASE; GENE TARGETING; GENE THERAPY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; REPERFUSION INJURY; RESTENOSIS; REVIEW;

EID: 0033858886     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060020-00001     Document Type: Review

References (33)

1. Is gene therapy for hypertension possible?
2. 1 receptor mRNA
3. Prevention of cardiac allograft arteriopathy by antisense Cdc2 kinase oligonucleotide
4. Genetic manipulation of vein grafts
5. The sixth report of the Joint National Committee on the prevention, detection, evaluation and treatment of high blood pressue
6. Effects of captopril on ischemic events after myocardial infarction: Results of the Survival and Ventricular Enlargement trial. SAVE investigators
7. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization
8. Direct intramuscular injection of plasmid DNA encoding angniopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb
9. Systemic delivery of antisense against angiotensinogen mRNA by adeno-associated plasmid vector decreases hypertension
10. 1 receptor in vascular smooth muscle cells using adeno-associated virus-based vectors
11. Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension
12. 1-R mRNA antisense
13. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide
14. Antisense oligonucleotide eliminates in vivo expression of c-fos in mammalian brain
15. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides
16. 1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin
17. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia
18. Uptake and efflux of intact antisense phosphorothioate deoxyoligonucleotide directed against angiotensin receptors in bovine adrenal cells
19. Antisense inhibition of β1-adrenoceptor mRNA in a single dose produces a profound and prolonged reduction in high blood pressure in spontaneously hypertensive rats
20. Inhibition of hypertension by peripheral administration of antisense oligodeoxynucleotides
21. Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen
22. 1 angiotensin receptor mRNA in spontaneously hypertensive rats
23. Intravenous injection with antisense oligodeoxynucleotides against angiotensinogen decreases blood pressure in spontaneously hypertensive rats
24. 1 receptor mRNA in brain and blood
25. Increase in angiotensin II type 1 receptor expression immediately following ischemia-reperfusion in isolated rat hearts
26. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo
27. Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery
28. Antisense oligodeoxynucleotides prevent acute cardiac allograft rejection via a novel, nontoxic, highly efficient transfection method
29. Intimal hyperplasia after vascular injury is inhibited by antisense cdk2 kinase oligonucleotides
30. Recombinant platelet-derived growth factor B gene expression in porcine arteries induces intimal hyperplasia in vivo
31. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial
32. 1 antisense oligodeoxynucleotides